<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Amylin Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/amylin-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AAPL) Guide to the 25 Cheapest ETFs &#8211; ETF News And Commentary</title>
		<link>http://www.stockbloghub.com/2012/05/18/aapl-guide-to-the-25-cheapest-etfs-etf-news-and-commentary/100548</link>
		<comments>http://www.stockbloghub.com/2012/05/18/aapl-guide-to-the-25-cheapest-etfs-etf-news-and-commentary/100548#comments</comments>
		<pubDate>Fri, 18 May 2012 15:45:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[AJG]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Arthur J Gallagher & Company]]></category>
		<category><![CDATA[BND]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines Corporation]]></category>
		<category><![CDATA[iShares S&P 500 Index]]></category>
		<category><![CDATA[IVV]]></category>
		<category><![CDATA[MCRS]]></category>
		<category><![CDATA[Micros Systems Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[SOA]]></category>
		<category><![CDATA[Solutia Inc.]]></category>
		<category><![CDATA[SPDRs]]></category>
		<category><![CDATA[SPN]]></category>
		<category><![CDATA[SPY]]></category>
		<category><![CDATA[Superior Energy Services Inc.]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Vanguard Europe Pacific ETF]]></category>
		<category><![CDATA[Vanguard Large Cap ETF]]></category>
		<category><![CDATA[Vanguard REIT Index ETF]]></category>
		<category><![CDATA[Vanguard Total Bond Market ETF]]></category>
		<category><![CDATA[Vanguard Total Stock Market ETF]]></category>
		<category><![CDATA[VEA]]></category>
		<category><![CDATA[VNQ]]></category>
		<category><![CDATA[VTI]]></category>
		<category><![CDATA[VV]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=100548</guid>
		<description><![CDATA[There are several factors that influence the decision of selecting an ETF for investment. Such factors include the past performance, holdings, sector exposure and concentration. Beyond these examples, expenses can also play an important role in the decision making process as well. The expense ratio of an asset fund refers to the total percentage of fund assets that are taken on a yearly basis to pay for administrative, management, advertising and all other costs that go into running an ETF. While these ratios are much smaller for ETFs than they are for mutual funds on average, investors should note that expenses still play a crucial role in determining the best fund in a segment. Furthermore, while many products may appear similar on the surface—with similar industry, holdings, and market cap ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/05/18/aapl-guide-to-the-25-cheapest-etfs-etf-news-and-commentary/100548/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Risk-Reward Balanced at Alkermes</title>
		<link>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426</link>
		<comments>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426#comments</comments>
		<pubDate>Wed, 07 Mar 2012 17:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94426</guid>
		<description><![CDATA[We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (ELN). The merger has expanded the portfolio significantly resulting in a 185.7% increase in revenues during the quarter. The expanded portfolio caused management to increase the 2012 revenue projection. Revenues are projected in the range of $370-$400 million, up from the previous guidance of $350-$380 million. Given the expanded product portfolio, we expect the company to achieve/beat the increased guidance. Consequently, the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Posts Lower Loss</title>
		<link>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689</link>
		<comments>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:38:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[iShares S&P Target Date 2010]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NICE Systems Limited]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TZD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85689</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 million milestone payment, increased 12.1% to $175 million. Revenues exceeded the Zacks Consensus Estimate of $166 million. Quarterly Details Quarterly revenues consisted of $155.1 million in product sales (up 0.7%) and $19.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Collaborative revenues included a $15 million milestone payment from Lilly on the launch of Bydureon in the EU. Collaborative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) A Busy Week Ahead &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152</link>
		<comments>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152#comments</comments>
		<pubDate>Mon, 17 Oct 2011 15:31:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Access National Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Alliance Financial Corporation]]></category>
		<category><![CDATA[ALNC]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AN]]></category>
		<category><![CDATA[ANCX]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[APOL]]></category>
		<category><![CDATA[Apollo Group Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[AutoNation Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBND]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BigBand Networks Inc]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bottomline Technologies Inc]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[BRKL]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brookline Bancorp Inc]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CKH]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Community Trust Bancorp Inc]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTBI]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Diamondrock Hospitality Company]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[Dominos Pizza Inc.]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DPZ]]></category>
		<category><![CDATA[DRH]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[ENZ]]></category>
		<category><![CDATA[Enzo Biochem Inc]]></category>
		<category><![CDATA[EPAY]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIN]]></category>
		<category><![CDATA[FHN]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Bankshares Inc]]></category>
		<category><![CDATA[First Horizon National Corporation]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flexsteel Industries Inc]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FLXS]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FSI International Inc]]></category>
		<category><![CDATA[FSII]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HA]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Hawaiian Holdings Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HCBK]]></category>
		<category><![CDATA[HCCI]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[Heritage-Crystal Clean Inc]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[Hudson City Bancorp Inc]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[Knight Transportation Inc]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[KNX]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Lakeland Bancorp Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LBAI]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Linear Technology Corporation]]></category>
		<category><![CDATA[LLTC]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Mattson Technology Inc]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MTSN]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OKSB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORB]]></category>
		<category><![CDATA[Orbital Sciences Corporation]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[Parker Hannifin Corporation]]></category>
		<category><![CDATA[Patni Computer Systems Limited]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[Pixelworks Inc]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[PXLW]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[RCKY]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[ROC]]></category>
		<category><![CDATA[Rockwood Holdings Inc.]]></category>
		<category><![CDATA[Rocky Brands Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[Safe Bulkers Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SB]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCL]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Seacor Holdings Inc.]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Shaw Communications Inc.]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SIVB]]></category>
		<category><![CDATA[SJR]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[SONC]]></category>
		<category><![CDATA[Sonic Corporation]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Southwest Bancorp Inc]]></category>
		<category><![CDATA[Spartan Stores Inc.]]></category>
		<category><![CDATA[SPTN]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Stepan Company]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVB Financial Group]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[Travelzoo Inc.]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[TZOO]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNF]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[UniFirst Corporation]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USA Truck Inc.]]></category>
		<category><![CDATA[USAK]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[USG]]></category>
		<category><![CDATA[USG Corporation]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[Viad Corporation]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VVI]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Washington Federal Inc]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WDFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WFSL]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85152</guid>
		<description><![CDATA[Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&#38;P 500. Thus, by the end of the week we will have a very good idea of how the overall season will go. Not only will there be a lot of reports, but many of those we get will be very important ones. The table at the end of this report reads like a who’s who of American industry, including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Citigroup (C), General Electric (GE), Goldman Sachs (GS), IBM (IBM), Intel (INTC) and McDonald’s (MCD). And that&#8217;s just the first half of the alphabet! ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes</title>
		<link>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265</link>
		<comments>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:38:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83265</guid>
		<description><![CDATA[Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who had not received any treatment before or previously received only one oral anti-diabetic drug (OAD), led to greater improvements in glycaemic control than those who had been dosed two or more OAD’s. The second trial showed that when type II diabetes patients switched from oral treatment with Merck’s (MRK) Januvia to injectable Victoza (once daily) experienced increased treatment satisfaction as well as significant reductions in blood glucose and body weight. We remind investors that in June this year, Novo Nordisk had presented data from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs</title>
		<link>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027</link>
		<comments>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:23:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80027</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second quarter revenues declined 3.8% to $158.1 million. Revenues, however, exceeded the Zacks Consensus Estimate of $156 million. Quarterly Details Total revenues for the quarter declined mainly due to lower net product sales. Quarterly revenues consisted of $154.8 million in product sales (down 4.8%) and $3.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $129 million in sales of Byetta (exenatide) and $25.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Late Stage Degludec Data</title>
		<link>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249</link>
		<comments>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78249</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type II diabetes. Novo Nordisk presented data from two, late stage, 52-week clinical trials, one in patients with type I and the other in victims of type II diabetes. These data were presented at the American Diabetes Association. Degludec particularly reduced nocturnal hypoglycemia (night-time episodes of excessively low blood sugar) versus Lantus in patients with type I or type II diabetes. Nocturnal hypoglycemia is highly feared by diabetics, and hence a reduced threat of it represents a real commercial edge for Degludec. Apart from the two studies, Novo Nordisk also presented data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Diabetes Study Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:42:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77767</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The first study showed that treatment with Victoza (once daily) in combination with metformin and/or sulfonylurea caused more patients to achieve control over their blood sugar levels compared to those treated with other commonly used diabetes drugs like Merck’s (MRK) Januvia and Amylin Pharmaceuticals’ (AMLN) Byetta. Moreover, data also revealed that patients underwent significant weight loss on switching over to Victoza therapy from Januvia. Novo Nordisk also presented data from another late stage study which investigated the effect of adding Levemir to the existing treatment regimen of Victoza and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334</link>
		<comments>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77334</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. We are positive on Alkermes’ decision to buy  Elan Corporation’s (ELN) drug delivery unit. The deal is expected to boost Alkermes’ cash earnings immediately following its closure. The product portfolio at Alkermes will be strengthened following the merger. Alkermes currently has two marketed drugs namely Risperdal Consta and Vivitrol in its product portfolio. Risperdal Consta is marketed worldwide by Johnson &#38; Johnson (JNJ) for the treatment of schizophrenia and bipolar disorder. The drug is manufactured by Alkermes. The other approved product at Alkermes is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval</title>
		<link>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181</link>
		<comments>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77181</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received a boost with the European Commission granting marketing authorization to Bydureon (exenatide once-weekly) for the treatment of type II diabetes. Bydureon is the first once-weekly treatment to gain approval for type II diabetes. Approval was granted for use in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione. EU Approval Was Expected EU approval was expected as, earlier in April, Bydureon had received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). While anticipated, the final approval of Bydureon, nevertheless, comes as a relief for Amylin which has recently been at the receiving end of a series ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly Launches Type II Diabetes Treatment Tradjenta</title>
		<link>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604</link>
		<comments>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[RAD]]></category>
		<category><![CDATA[Rite Aid Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76604</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the US. Tradjenta, which has been priced at $6.77 per tablet, is available at Walgreen (WAG), CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and several other leading chain and independent pharmacies as well. Eli Lilly and Boehringer are working on gaining formulary coverage for the product and are looking to get Tradjenta reimbursed at a co-pay level similar to other preferred branded products. Eli Lilly and Boehringer’s strategic alliance, signed in Jan 2011, is focused on bringing new diabetes treatments to market. However, in May 2011, Eli Lilly’s exenatide partner, Amylin Pharmaceuticals, Inc. (AMLN) filed a lawsuit against Eli Lilly. Amylin claimed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates</title>
		<link>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977</link>
		<comments>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:35:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71977</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. First quarter revenues declined 12.3% to $152.7 million. Revenues also missed the Zacks Consensus Estimate of $155 million. Quarterly Details Total revenues for the quarter declined 12.3% mainly due to lower net product sales. Quarterly revenues consisted of $150.8 million in product sales (down 12.5%) and $1.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $128 million in sales of Byetta (exenatide) and $22.8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon</title>
		<link>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813</link>
		<comments>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813#comments</comments>
		<pubDate>Tue, 19 Apr 2011 03:32:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71813</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received good news regarding their pipeline candidate, Bydureon (exenatide once-weekly). Amylin, Eli Lilly and Alkermes said that Bydureon received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP issued an opinion in favor of approving Bydureon for the treatment of type II diabetes in combination with certain oral therapies. A final decision regarding the approvability of Bydureon should be delivered by the European Commission in 2-3 months. Approval would make Bydureon the first once-weekly type II diabetes treatment in the EU. The positive EU recommendation comes as a relief for Amylin which has recently been at the receiving end of a series of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498</link>
		<comments>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498#comments</comments>
		<pubDate>Tue, 29 Mar 2011 14:41:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68498</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and the year-ago loss of $1.20. Full year revenues came in at $668.8 million, down 11.8%. Despite a decline in revenues, Amylin posted better-than-expected results due to lower expenses. We believe the company will continue controlling costs and have reduced our 2011 loss estimate by 22 cents. Meanwhile, Amylin faced a huge setback in 2010 when it failed to gain approval for its lead pipeline candidate, Bydureon, for the second time. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were looking to get Bydureon approved for the treatment of type II diabetes. On the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Releases Disappointing Data</title>
		<link>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116</link>
		<comments>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116#comments</comments>
		<pubDate>Mon, 28 Mar 2011 22:25:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68116</guid>
		<description><![CDATA[Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve its primary endpoint of non-inferiority in the DURATION-6 study, which compared Bydureon with Novo Nordisk’s (NVO) Victoza. Results showed that patients in the Bydureon arm achieved a reduction of 1.3 percentage points in A1C levels compared to a reduction of 1.5 percentage points in the Victoza arm. Although gastrointestinal adverse events were less frequent in the Bydureon arm, the candidate’s failure to achieve the primary endpoint is a major setback. The disappointing DURATION-6 data is the latest setback faced by Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), in the development of Bydureon. Earlier in October 2010, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415</link>
		<comments>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415#comments</comments>
		<pubDate>Mon, 20 Dec 2010 22:36:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60415</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year ago loss of $0.19. Lower revenues resulted in the wider loss. Both Byetta and Symlin revenues declined on a sequential as well as year-over-year basis. Moreover, Amylin faced a huge setback when it failed to gain approval for its lead pipeline candidate, Bydureon, for the second time. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were looking to get Bydureon approved for the treatment of type II diabetes. The latest complete response letter (CRL), which came a few days ahead of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes 2010 Second Quarter Revenues Rise &#8211; View Lowered</title>
		<link>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507</link>
		<comments>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:59:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58507</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per share. The narrower-than-expected loss was attributable to the higher revenues recorded in the quarter. Total revenues for the reported quarter climbed 2% to $49.2 million. The increase was primarily attributable to higher manufacturing, royalty and sales revenues. Revenues for the reported quarter surpassed the Zacks Consensus Estimate of $43 million. We note that Alkermes derives the bulk of its revenue from schizophrenia drug Risperdal Consta. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes generated $32.6 million from manufacturing the drug in the reported quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006</link>
		<comments>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:44:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59006</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower revenues resulted in the wider loss. Revenues of $156.1 million missed the Zacks Consensus Estimate of $159 million. Quarterly Details Total revenues for the quarter declined 19.5% mainly due to lower net product sales. Quarterly revenues consisted of $154.0 million in product sales and $2.1 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $132.4 million in sales of Byetta (exenatide) and $21.6 million in sales of Symlin. Both Byetta and Symlin revenues declined on a sequential ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Vivitrol Earns US Food and Drug Administration Clearance</title>
		<link>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320</link>
		<comments>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:20:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55320</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid detoxification. Opioid dependence refers to a chronic ailment of the brain. The approval of Vivitrol, already available for the treatment of alcohol dependence for which it gained FDA approval in 2006, for the additional indication does not surprise us. Last month, an advisory panel of the FDA had recommended the approval of Vivitrol for treating opioid dependence. The FDA’s Psychopharmacologic Drugs Advisory Committee voted 12-1 in favor of approving Vivitrol for the additional indication. We remind investors that the supplemental New Drug Application (sNDA), seeking to expand Vivitrol’s label, was submitted in April 2010. The application was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb&#8217;s Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259</link>
		<comments>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259#comments</comments>
		<pubDate>Fri, 15 Oct 2010 18:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55259</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814). The patients enrolled in the study, were above 18 years of age and had responded unsatisfactorily to treatment by metformin alone. Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion thereby leading to elevated glucose levels. Results from the 52 week study, presented at the European Association for the Study of Diabetes (EASD), revealed that a combination of dapagliflozin and metformin was as effective as the combination of glipizide and metformin in reducing blood sugar ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798</link>
		<comments>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:33:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52798</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814). The patients enrolled in the study, were more than or equal to 18 years of age and had responded unsatisfactorily to treatment by metformin alone. Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes, which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion, thereby leading to elevated glucose levels. Results from the 52 week study, presented at the European Association for the Study of Diabetes (EASD), revealed that a combination of dapagliflozin and metformin was as effective as the combination of glipizide and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Diabetes Drug Candidate Encourages</title>
		<link>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428</link>
		<comments>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428#comments</comments>
		<pubDate>Wed, 22 Sep 2010 03:17:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52428</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, international, randomized, parallel-group, double-blind, placebo-controlled study (n=597). Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion thereby leading to elevated glucose levels. Results from the 24 week study, presented at the European Association for the Study of Diabetes (EASD) revealed that a combination of dapagliflozin and glimepiride was more effective in reducing blood sugar levels compared to glimepiride and a placebo. Moreover, the weight reduction was higher in patients treated with the combination of dapagliflozin and glimepiride. Patients receiving dapagliflozin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Earnings Report Shows Revenues Dipped</title>
		<link>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206</link>
		<comments>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206#comments</comments>
		<pubDate>Tue, 10 Aug 2010 17:40:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47206</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of  14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per share. Quarterly Results Total revenues for the reported quarter declined 11% to $42.3 million. The decline was primarily attributable to lower manufacturing revenues related to the schizophrenia drug Risperdal Consta, which is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes.  Revenues were also marginally short of the Zacks Consensus Revenue Estimate of $43 million. Manufacturing revenues slipped 7% in the reported quarter to $26.9 million. Manufacturing revenues included $26.3 million from Risperdal Consta. Manufacturing revenues also included $0.6 million related to the manufacture of polymer for Byetta once-weekly (proposed trade name: Bydureon). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data on Diabetes Candidate Bydureon</title>
		<link>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922</link>
		<comments>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922#comments</comments>
		<pubDate>Tue, 29 Jun 2010 18:02:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41922</guid>
		<description><![CDATA[Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly &#38; Co. (LLY), the co-developers of type II diabetes candidate Bydureon (exenatide once weekly), presented pooled safety data on the candidate. The companies presented the data at the 70th Annual Scientific Sessions of the American Diabetes Association held in Orlando. The data came from an analysis of the results of three randomized, double-blind studies, which revealed that Bydureon was well tolerated. The studies involved patients treated with either Bydureon (n=541) or other diabetes treatments such as Merck’s (MRK) Januvia, Takeda’s Actos or Sanofi-Aventis’ (SNY) Lantus (n=554). The number of patients opting out of the studies due to serious adverse events was low. Severe hypersensitivity reactions such as serious skin reactions or anaphylaxis were not observed in any of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Reports Encouraging Diabetes Therapy Data</title>
		<link>http://www.stockbloghub.com/2010/06/28/bmy-bristol-myers-squibb-reports-encouraging-diabetes-therapy-data/41855</link>
		<comments>http://www.stockbloghub.com/2010/06/28/bmy-bristol-myers-squibb-reports-encouraging-diabetes-therapy-data/41855#comments</comments>
		<pubDate>Tue, 29 Jun 2010 00:04:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41855</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Co. (BMY) reported encouraging results from a late-stage study evaluating the combination therapy of Onglyza (saxagliptin) and metformin in patients suffering from type II diabetes. Onglyza has been co-developed by Bristol-Myers and AstraZeneca Plc (AZN). The data were presented at the 70th American Diabetes Association Annual Scientific Sessions. The results from the multicenter, randomized, double-blind, active-controlled study revealed that the combination therapy led to long-term glycemic improvement in previously untreated patients suffering from type II diabetes. Glycemic control refers to the levels of blood sugar (glucose) in a person suffering from diabetes. The disease was unsatisfactorily controlled by diet and exercise compared with a 10 mg dose of saxagliptin or metformin alone. Onglyza is under review in more than 58 countries across the globe. The drug has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/28/bmy-bristol-myers-squibb-reports-encouraging-diabetes-therapy-data/41855/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Narrows Loss</title>
		<link>http://www.stockbloghub.com/2010/04/20/amln-amylin-pharmaceuticals-narrows-loss/34378</link>
		<comments>http://www.stockbloghub.com/2010/04/20/amln-amylin-pharmaceuticals-narrows-loss/34378#comments</comments>
		<pubDate>Tue, 20 Apr 2010 21:34:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34378</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 27 cents per share in the first quarter of 2010, a cent below the Zacks Consensus Estimate and well below the year ago loss of 34 cents. Lower expenses helped the company narrow its loss despite a decline in revenues. Total revenues for the quarter declined 3.5% to $174.1 million, mainly due to lower net product sales. Quarterly revenues consisted of $172.3 million in product sales and $1.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $149.8 million in sales of Byetta (exenatide) and $22.5 million in sales of Symlin. While Symlin revenues increased both on a sequential and year-over-year basis, Byetta revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/20/amln-amylin-pharmaceuticals-narrows-loss/34378/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk&#8217;s Victoza Proves More Effective</title>
		<link>http://www.stockbloghub.com/2010/03/31/nvo-novo-nordisks-victoza-proves-more-effective/32423</link>
		<comments>http://www.stockbloghub.com/2010/03/31/nvo-novo-nordisks-victoza-proves-more-effective/32423#comments</comments>
		<pubDate>Wed, 31 Mar 2010 19:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32423</guid>
		<description><![CDATA[Recently, results from Novo Nordisk’s (NVO) LEAD 6 extension study was published in Diabetes Care. The study aimed at evaluating the efficacy and safety of switching from Amylin Pharmaceuticals (AMLN) and Eli Lilly’s (LLY) Byetta (exenatide) to Novo Nordisk’s Victoza. The LEAD 6 study was conducted over 26 weeks on 389 patients, which compared the effectiveness and safety of once a day Victoza (1.8 milligrams plus oral anti diabetes drug (OAD)) to twice daily Byetta (10 micrograms plus OAD). It was observed that patients taking Victoza showed better results in lowering blood sugar and fasting glucose level compared to Byetta. In Jan 2010, Victoza received approval from the US Food and Drug Administration (FDA) for the treatment of type II diabetes in adults. The drug is approved for use with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/nvo-novo-nordisks-victoza-proves-more-effective/32423/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review</title>
		<link>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187</link>
		<comments>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32187</guid>
		<description><![CDATA[Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359</link>
		<comments>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:30:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31359</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose early-stage trial is designed to assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37. Approximately 24 healthy volunteers will be studied for a period of one week. The study will see two dose levels of ALKS 37 being tested in sequential cohorts. This study comes after the completion of a previous single dose clinical study in healthy volunteers. In that study ALKS 37 was generally well tolerated and demonstrated low systemic exposure across ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Drug Approval Delayed</title>
		<link>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769</link>
		<comments>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769#comments</comments>
		<pubDate>Tue, 16 Mar 2010 21:44:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30769</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc.’s (ALKS) once weekly formulation of Byetta (exenatide). The companies are seeking to get Byetta once weekly (proposed trade name: Bydureon) approved for the treatment of type II diabetes. Despite the delay, both Amylin and Alkermes shares were up significantly as the agency did not ask the companies to conduct additional clinical or pre-clinical studies. This is encouraging news as additional studies would have delayed approval significantly. We were concerned that safety issues surrounding the use of glucagon-like peptide-1 (GLP-1) molecules like exenatide could have led to the FDA asking for additional safety studies. However, we believe that the final label for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Application Gets New Target Date</title>
		<link>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381</link>
		<comments>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381#comments</comments>
		<pubDate>Mon, 01 Mar 2010 22:57:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29381</guid>
		<description><![CDATA[Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate, exenatide once-weekly. Exenatide once-weekly is co-developed by Alkermes Inc. (ALKS), Eli Lilly (LLY) and Amylin Pharmaceuticals Inc. (AMLN). The U.S. agency has set March 12, 2010 as the new target date. Originally, the FDA was scheduled to decide on the drug by March 5, 2010. In July 2009, the FDA accepted the NDA for the candidate. The NDA was filed by the three companies in May 2009. Exenatide once-weekly is an injectable formulation of Amylin’s Byetta (exenatide). Byetta is an injection administered twice daily. Exenatide once-weekly has enormous market potential in the $13 billion type II diabetes market. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Obesity Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994</link>
		<comments>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994#comments</comments>
		<pubDate>Thu, 25 Feb 2010 23:18:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28994</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies. The decision is based on encouraging 52-week results on the combination treatment from a blinded, placebo-controlled phase II extension study in which the combination succeeded in achieving the key target of sustained and robust weight loss. Results showed that patients who continued treatment with pramlintide/metreleptin for 52 weeks experienced sustained weight loss, while those on placebo regained almost all of their weight. The combination treatment was found to be most effective in patients with a body mass index (BMI) less than 35 kg/m2. The combination treatment was generally well tolerated, with nausea and injection-site-adverse events being the most common side effects ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Pipeline Announces Good News</title>
		<link>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257</link>
		<comments>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257#comments</comments>
		<pubDate>Wed, 17 Feb 2010 22:40:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28257</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). Alkermes intends to present full results from the early-stage study at a future medical meeting. The randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacokinetics of a single oral administration of 5 ascending doses of the candidate, ranging from 1 mg to 100 mg, in 40 healthy volunteers. The data revealed the presence of low systemic exposure at doses up to 100 mg. The finding was consistent with prior preclinical studies which showed that ALKS 37 targets the gastrointestinal tract with limited systemic exposure ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Retains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398</link>
		<comments>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398#comments</comments>
		<pubDate>Tue, 09 Feb 2010 03:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27398</guid>
		<description><![CDATA[We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. Alkermes has two approved products on the market. Its lead product, Risperdal Consta (or simply Consta), was developed for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes also receives royalty revenues on Consta sales. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). The drug is approved in over 75 countries worldwide and marketed in over 50 countries, but the US is clearly the key ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Misses Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/30/amln-amylin-pharmaceuticals-misses-earnings-estimates/26423</link>
		<comments>http://www.stockbloghub.com/2010/01/30/amln-amylin-pharmaceuticals-misses-earnings-estimates/26423#comments</comments>
		<pubDate>Sat, 30 Jan 2010 21:13:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26423</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 32 cents per share in the fourth quarter of 2009, five cents wider than the Zacks Consensus Estimate of 27 cents. The company had reported a net loss of 37 cents in the year-ago quarter. For the full year 2009, net loss came in at $1.20, narrower than the Zacks Consensus Estimate of $1.22 and the year-ago net loss of $1.95. Total revenues for the quarter were $185.5 million, relatively unchanged from the year-ago period’s revenues. Quarterly revenues consisted of $184.3 million in product sales and $1.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Full year total revenues declined 1.5% to $758.4 million. Full year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/30/amln-amylin-pharmaceuticals-misses-earnings-estimates/26423/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Impresses in Head-to-Head</title>
		<link>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067</link>
		<comments>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067#comments</comments>
		<pubDate>Thu, 17 Dec 2009 05:21:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23067</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) recently announced positive results on its once weekly formulation of Byetta (referred to as exenatide once weekly), which is being developed in collaboration with Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS). Amylin presented results from a head-to-head study (DURATION-5) comparing exenatide once weekly with a Byetta injection taken twice daily in patients with type II diabetes. Data showed that after 24 weeks of treatment, patients on exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months (1.6 percentage points versus 0.9 percentage points). While both treatment groups achieved statistically significant weight loss by the end of the study, the average loss was higher in the once-weekly group compared to the Byetta group (5.1 pounds versus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin and Eli Lilly&#8217;s Byetta Label Revised</title>
		<link>http://www.stockbloghub.com/2009/11/29/amln-amylin-and-eli-lillys-byetta-label-revised/21457</link>
		<comments>http://www.stockbloghub.com/2009/11/29/amln-amylin-and-eli-lillys-byetta-label-revised/21457#comments</comments>
		<pubDate>Mon, 30 Nov 2009 04:52:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21457</guid>
		<description><![CDATA[Earlier this month, Amylin (AMLN) and Eli Lilly (LLY) announced that the U.S. Food and Drug Administration (FDA) has implemented label changes for Byetta (exenatide) which is indicated for the treatment of type II diabetes. The revised label will inform both patients as well as doctors about the possibility of kidney function problems arising with the use of Byetta. The label has been revised to include information on post-marketing reports of altered kidney function Incorporatedluding acute renal failure and insufficiency. The label says that Byetta should not be used in patients with end-stage kidney disease or several kidney impairment and recommends that physicians should be cautious about starting patients on Byetta or increasing their doses if the patients have moderate kidney problems or if they have had a kidney transplant. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/29/amln-amylin-and-eli-lillys-byetta-label-revised/21457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861</link>
		<comments>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861#comments</comments>
		<pubDate>Wed, 18 Nov 2009 22:51:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20861</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage trial (n=250) demonstrated that subjects injected with Vivitrol (naltrexone for extended-release injectable suspension) once a month were more likely to pass a urine test compared to recipients of a placebo injection. Furthermore, subjects reported a lower craving for drugs, and half the subjects came clean in at least 90% of their drug tests. The subjects were addicted to opioid drugs including heroin. Before enrolling for the trial, they had to stay away from drugs for at least a week. The most common adverse event affecting patients during the study were inflammation of the nose and throat in addition to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Amylin Pharmaceuticals Strikes First on Obesity</title>
		<link>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415</link>
		<comments>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:30:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19415</guid>
		<description><![CDATA[Almost all of the news in the obesity race has been made recently by three small biotech companies &#8212; Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race. Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesity. As part of the transaction, Amylin will receive a one-time up-front payment of $75 million from Takeda. Amylin is also eligible to receive additional payments based on development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Loss Narrows</title>
		<link>http://www.stockbloghub.com/2009/10/21/amln-amylin-pharmaceuticals-loss-narrows/18390</link>
		<comments>http://www.stockbloghub.com/2009/10/21/amln-amylin-pharmaceuticals-loss-narrows/18390#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18390</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a loss of 19 cents per share in the third quarter, which was narrower than the Zacks Consensus Estimate of a loss of 30 cents. In the prior-year period, the company had incurred a loss of 47 cents. Total revenues for the quarter were $211.2 million, down 3.3% year over year. Revenues consisted of $192.9 million in product sales and $18.3 million in collaborative payments from partner Eli Lilly (LLY). Product sales comprised $171.1 million in sales of Byetta and $21.8 million in sales of Symlin. Byetta sales declined both on a yearly and sequential basis. The company attributed the sequential decline in Byetta sales to an increase in wholesaler stocking in the previous quarter. We believe Byetta continues to be affected by safety issues surrounding ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/amln-amylin-pharmaceuticals-loss-narrows/18390/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689</link>
		<comments>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689#comments</comments>
		<pubDate>Fri, 16 Oct 2009 22:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17689</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its pipeline candidate, ALKS33, for addiction and nervous system disorders, gave positive results in two early stage clinical trials. Results from the two studies, ALK33-003 and ALK33-004, demonstrated that the candidate blocked the effects of an opioid with an action duration that supported once daily dosing. The studies were initiated in May this year. ALK33-003, a randomized, double-blind, placebo-controlled, multi-dose study, evaluated the pharmacokinetics, safety and tolerability of multiple doses of ALKS33 in 30 healthy volunteers. ALK33-004, a randomized, single-blind, placebo-controlled, single-dose study, was designed to examine the ability of ALKS33 to block the effects of an opioid following a single oral dose of ALKS33 in 24 healthy, non-dependent, opioidexperienced subjects. ALKS33, an oral opioid modulator, was generally well-tolerated in both the studies. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Mixed News for Merck Drug</title>
		<link>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330</link>
		<comments>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:59:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com.php5-2.dfw1-2.websitetestlink.com/?p=16330</guid>
		<description><![CDATA[Last week, Merck (MRK) received a favorable opinion from the European Medicines Agency&#8217;s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin). The committee recommended the drugs to be used as add-ons to insulin for the treatment of type 2 diabetes. In the US, a supplemental New Drug Application (sNDA) for the use of Januvia and Janumet in combination with insulin has been accepted by the FDA and is currently under review. While the favorable opinion from the committee is good news, we remain concerned about the risk of inflamed pancreas for patients treated with Januvia or Janumet. Although the company officials refuse to accept the link, the FDA has stated that 88 cases of acute pancreatitis Incorporatedluding two ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Amylin Pharmaceuticals Collaborates with Biocon</title>
		<link>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973</link>
		<comments>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14973</guid>
		<description><![CDATA[Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin&#8217;s &#8220;phybrid&#8221; technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

